Sanofi-a Ventis Deutschland Gmbh

Mcmaster University

University of Ulster

Sibylle Hess

Thorsten Sadowski

Hertzel Gerstein

Gregory Steinberg

Guillaume Pare

Laurent Pradier

Andrees Bohme

Veronique Taupin

Andrees Boehme

Agnes Menut

Christian Hölscher

Christian Holscher

Véronique Taupin

Christian Hoelscher

Christian HÖLSCHER

Andrees BÖHME

The present invention relates to metformin for use in treating a patient, wherein the patient exhibits an increased level of GDF15 in response to metformin treatment; to methods of identifying a patient who will benefit or who will not benefit from metformin treatment; methods of treating a patient at risk of developing or suffering from a disease or disorder comprising administering therapeutically effective amount of metformin; methods of adapting the dosage of metformin; the usage of GDF15 as biomarker for identifying a patient who will benefit or who will not benefit from metformin treatment, kits for use in identifying a patient who will benefit from metformin treatment and the use of the kits, as well as methods of treating a patient or who will not benefit from metformin treatment.

Growth differentiation factor 15 as biomarker for metformin

The present invention refers to a pharmaceutical composition for use in the treatment of a neurodegenerative disease.

Pharmaceutical composition for use in the treatment of a neurodegenerative disease

The present application relates to a pharmaceutical composition for use in the prevention or/and treatment of a neurodegenerative disease, the composition comprising desProExendin-4(1-39)-Lys-NHor/and a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, adjuvant, or/and auxiliary substance. In addition, the present application relates to the use of the pharmaceutical composition for the treatment and prevention of a neurodegenerative disease.

Growing community of inventors

Frankfurt am Main, Germany

Sibylle Hess